| Symbol | AXSM |
|---|---|
| Name | AXSOME THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 22 CORTLANDT STREET,16TH FLOOR, NEW YORK, New York, 10007, United States |
| Telephone | +1 212 332-3241 |
| Fax | — |
| — | |
| Website | https://www.axsome.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001579428 |
| Description | Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. Additional info from NASDAQ: |
2026-06-26 11:00
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Read more
2026-06-15 11:00
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Read more
2026-06-12 00:34
JEFFS ROGER 🔴 sold 572 shares of Axsome Therapeutics, Inc. (AXSM) at $249.12 Transaction Date: Jun 10, 2026 | Filing ID: 268202
Read more
2026-06-11 21:09
📋 JEFFS ROGER (Director) plans to sell 286 shares of Axsome Therapeutics, Inc. (at $249.12 each, total $71K) Filed: Jun 11, 2026 | ID: 000636
Read more
2026-06-11 01:49
JEFFS ROGER 🟡 adjusted position in 0 shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Jun 08, 2026 | Filing ID: 266437
Read more
2026-06-11 01:49
Saad Mark E 🟡 adjusted position in 0 shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Jun 08, 2026 | Filing ID: 266436
Read more
2026-06-11 01:49
Mahony Susan 🟡 adjusted position in 600 shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) at $246.18 Transaction Date: Jun 08, 2026 | Filing ID: 266435
Read more
2026-06-11 01:49
Coleman Mark 🟡 adjusted position in 643 shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) at $249.00 Transaction Date: Jun 08, 2026 | Filing ID: 266433
Read more
2026-06-10 20:17
📋 Mahony Susan (Director) plans to sell 300 shares of Axsome Therapeutics, Inc. (at $246.18 each, total $74K) Filed: Jun 10, 2026 | ID: 000633
Read more
2026-06-10 20:16
📋 JEFFS ROGER (Director) plans to sell 286 shares of Axsome Therapeutics, Inc. (at $246.18 each, total $70K) Filed: Jun 10, 2026 | ID: 000632
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07717879 | A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD | Phase3 | ADHD | Recruiting | 2026-07-06 | 2028-06-30 | ClinicalTrials.gov |
| NCT07717892 | A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With A… | Phase3 | ADHD | Recruiting | 2026-06-25 | 2028-06-30 | ClinicalTrials.gov |
| NCT07637162 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Phase3 | Fibromyalgia | Enrolling_By_Invitation | 2026-04-29 | 2028-05-01 | ClinicalTrials.gov |
| NCT07484217 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sle… | Phase3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Recruiting | 2026-02-23 | 2028-12-01 | ClinicalTrials.gov |
| NCT07398417 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal… | Phase3 | Fibromyalgia | Recruiting | 2026-01-14 | 2028-03-01 | ClinicalTrials.gov |
| NCT07523048 | Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive… | Phase2 | Major Depressive Disorder (MDD) | Recruiting | 2025-11-21 | 2027-01-01 | ClinicalTrials.gov |
| NCT06878976 | Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder | Phase3 | Binge-Eating Disorder | Enrolling_By_Invitation | 2025-02-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06736509 | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With D… | Phase3 | Agitation in Patients With Dementia of the Alzheimer's Type | Terminated | 2024-11-21 | 2025-04-25 | ClinicalTrials.gov |
| NCT06568367 | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shi… | Phase3 | Excessive Sleepiness | Recruiting | 2024-08-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06170970 | Solriamfetol for the Treatment of Multiple Sclerosis Fatigue | Phase2 | Multiple Sclerosis | Recruiting | 2024-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using… | Phase3 | Binge-Eating Disorder | Recruiting | 2024-04-26 | 2025-12-01 | ClinicalTrials.gov |
| NCT06360419 | Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfet… | Phase3 | Major Depressive Disorder | Completed | 2024-03-18 | 2025-03-26 | ClinicalTrials.gov |
| NCT06223880 | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing … | Phase4 | Major Depressive Disorder | Recruiting | 2023-12-27 | 2026-03-01 | ClinicalTrials.gov |
| NCT05838430 | Solriamfetol and CBT-I in Patients With Insomnia Disorder | Phase4 | Insomnia | Completed | 2023-07-31 | 2026-04-30 | ClinicalTrials.gov |
| NCT05972044 | A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD… | Phase3 | ADHD | Completed | 2023-07-06 | 2025-03-14 | ClinicalTrials.gov |
| NCT05557409 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer'… | Phase3 | Agitation in Patients With Dementia of the Alzheimer's Type | Completed | 2022-09-06 | 2024-12-21 | ClinicalTrials.gov |
| NCT05550207 | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a… | Phase3 | Migraine | Completed | 2022-08-31 | 2024-11-27 | ClinicalTrials.gov |
| NCT05113745 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in S… | Phase3 | Narcolepsy | Completed | 2021-10-20 | 2024-11-15 | ClinicalTrials.gov |
| NCT05059223 | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients Wi… | Phase3 | Narcolepsy | Completed | 2021-09-15 | 2024-03-15 | ClinicalTrials.gov |
| NCT05008341 | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Follo… | Phase1 | Narcolepsy | Completed | 2021-08-27 | 2022-04-15 | ClinicalTrials.gov |
| NCT04788953 | Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work D… | Phase4 | Excessive Sleepiness | Terminated | 2021-07-21 | 2024-04-19 | ClinicalTrials.gov |
| NCT04947553 | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With … | Phase3 | Agitation in Patients With Dementia of the Alzheimer's Type | Completed | 2021-06-17 | 2024-12-21 | ClinicalTrials.gov |
| NCT04789174 | Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Random… | Phase4 | Excessive Daytime Sleepiness | Completed | 2021-05-17 | 2022-09-19 | ClinicalTrials.gov |
| NCT04971291 | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients | Phase2 | Major Depressive Disorder | Unknown | 2021-04-14 | 2021-07-01 | ClinicalTrials.gov |
| NCT04797715 | Assessing Clinical Outcomes in Alzheimer's Disease Agitation | Phase3 | Agitation in Patients With Dementia of the Alzheimer's Type | Completed | 2020-12-31 | 2022-11-21 | ClinicalTrials.gov |
| NCT04634669 | Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) | Phase2 | Treatment Resistant Depression | Terminated | 2020-09-23 | 2022-03-04 | ClinicalTrials.gov |
| NCT04608396 | Mechanistic Evaluation of Response in TRD (MERIT) | Phase2 | Treatment Resistant Depression | Completed | 2020-08-13 | 2021-07-30 | ClinicalTrials.gov |
| NCT04163185 | Initiating Early Control of Migraine Pain and Associated Symptoms | Phase3 | Migraine | Completed | 2019-10-08 | 2020-03-23 | ClinicalTrials.gov |
| NCT06413420 | SUNOSI® (Solriamfetol) Pregnancy Registry | — | Narcolepsy | Recruiting | 2019-07-31 | 2029-09-01 | ClinicalTrials.gov |
| NCT04039022 | Open-Label Safety Study of AXS-05 in Subjects With Depression | Phase3 | Major Depressive Disorder | Completed | 2019-07-08 | 2020-10-23 | ClinicalTrials.gov |
| NCT04068051 | Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) | Phase3 | Migraine | Completed | 2019-07-06 | 2020-09-22 | ClinicalTrials.gov |
| NCT04019704 | A Trial of AXS-05 in Patients With Major Depressive Disorder | Phase3 | Depression | Completed | 2019-06-20 | 2019-12-05 | ClinicalTrials.gov |
| NCT03881852 | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Trea… | Phase2 | Narcolepsy | Completed | 2019-04-05 | 2019-11-27 | ClinicalTrials.gov |
| NCT03896009 | Maximizing Outcomes in Treating Acute Migraine | Phase3 | Migraine | Completed | 2019-03-04 | 2019-12-10 | ClinicalTrials.gov |
| NCT03595579 | Assessing Symptomatic Clinical Episodes in Depression | Phase2 | Major Depressive Disorder | Completed | 2018-05-30 | 2019-01-07 | ClinicalTrials.gov |
| NCT03471767 | AXS-05 Phase II Trial on Smoking Behavior | Phase2 | Smoking Cessation | Completed | 2018-03-25 | 2019-03-31 | ClinicalTrials.gov |
| NCT03226522 | Addressing Dementia Via Agitation-Centered Evaluation | Phase2 | Agitation in Patients With Dementia of the Alzheimer's Type | Completed | 2017-07-13 | 2020-04-17 | ClinicalTrials.gov |
| NCT02741791 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment … | Phase3 | Treatment Resistant Major Depressive Disorder | Completed | 2016-03-01 | 2020-03-20 | ClinicalTrials.gov |
| NCT02746068 | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA As… | Phase3 | Osteoarthritis, Knee | Unknown | 2016-03-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02504008 | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With … | Phase3 | Complex Regional Pain Syndrome | Unknown | 2015-07-01 | 2019-01-01 | ClinicalTrials.gov |
Total clinical trials: 40
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AXS-14 (esreboxetine) | Other | Phase PHASE3 | Fibromyalgia | ENROLLING_BY_INVITATION | NCT07637162 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| Solriamfetol 150 MG | Other | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| Placebo | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 300 mg | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 150 mg | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Placebo | Other | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| AXS-14 (Esreboxetine) | Other | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| Placebo | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717892 |
| Solriamfetol Dose B | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717892 |
| Solriamfetol Dose A | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717892 |
| Placebo | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717879 |
| Solriamfetol Dose B | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717879 |
| Solriamfetol Dose A | Other | Phase PHASE3 | ADHD | RECRUITING | NCT07717879 |
| AXS-05 (dextromethorphan-bupropion) | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | TERMINATED | NCT06736509 |
| Placebo | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| AXS-12 (Reboxetine) | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| AXS-14 (esreboxetine) | Other | Phase PHASE3 | Fibromyalgia | ENROLLING_BY_INVITATION | NCT07637162 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Solriamfetol | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Placebo | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05059223 |
| AXS-12 (reboxetine) | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05059223 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT05838430 |
| AXS-07 | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04068051 |
| Placebo | Other | Phase PHASE3 | Complex Regional Pain Syndrome | UNKNOWN | NCT02504008 |
| AXS-02 (oral zoledronate) | Other | Phase PHASE3 | Complex Regional Pain Syndrome | UNKNOWN | NCT02504008 |
| Placebo | Other | Phase PHASE3 | Osteoarthritis, Knee | UNKNOWN | NCT02746068 |
| AXS-02 | Other | Phase PHASE3 | Osteoarthritis, Knee | UNKNOWN | NCT02746068 |
| Bupropion | Other | Phase PHASE3 | Treatment Resistant Major Depressive Disorder | COMPLETED | NCT02741791 |
| AXS-05 | Other | Phase PHASE3 | Treatment Resistant Major Depressive Disorder | COMPLETED | NCT02741791 |
| Bupropion SR | Other | Phase PHASE2 | Major Depressive Disorder | UNKNOWN | NCT04971291 |
| AXS-05 | Other | Phase PHASE2 | Major Depressive Disorder | UNKNOWN | NCT04971291 |
| Bupropion | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03595579 |
| AXS-05 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03595579 |
| Placebo | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT04608396 |
| AXS-05 | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT04608396 |
| AXS-05 (dextromethorphan and bupropion) oral tablets | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04039022 |
| Placebo | Other | Phase PHASE3 | Depression | COMPLETED | NCT04019704 |
| AXS-05 | Other | Phase PHASE3 | Depression | COMPLETED | NCT04019704 |
| Bupropion SR | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03471767 |
| AXS-05 | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03471767 |
| Solriamfetol 150 mg Oral Tablet | Other | Phase PHASE1 | Narcolepsy | COMPLETED | NCT05008341 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| Rizatriptan | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| Meloxicam | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| AXS-07 (MoSEIC meloxicam and rizatriptan) | Other | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| Placebo | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| AXS-12 (Reboxetine) | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| Placebo | Other | Phase PHASE2 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT03226522 |
| Bupropion | Other | Phase PHASE2 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT03226522 |
| AXS-05 | Other | Phase PHASE2 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT03226522 |
| Placebo | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT04797715 |
| AXS-05 | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT04797715 |
| No treatment | Drug | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Other prescription wake-promoting medications or stimulants | Drug | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Sunosi (solriamfetol) | Other | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Bupropion | Other | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| AXS-05 | Other | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| Placebo | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05059223 |
| AXS-12 (reboxetine) | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05059223 |
| Placebo | Other | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Monitoring | Other | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | Drug | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Solriamfetol 75 MG | Other | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Solriamfetol | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Placebo | Other | Phase PHASE4 | Excessive Sleepiness | TERMINATED | NCT04788953 |
| Solriamfetol Oral Tablet | Other | Phase PHASE4 | Excessive Sleepiness | TERMINATED | NCT04788953 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04163185 |
| AXS-07 (MoSEIC meloxicam and rizatriptan) | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04163185 |
| Placebo | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05113745 |
| AXS-12 (reboxetine) | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05113745 |
| Placebo | Other | Phase PHASE3 | Binge-Eating Disorder | RECRUITING | NCT06413433 |
| Solriamfetol 300 mg | Other | Phase PHASE3 | Binge-Eating Disorder | RECRUITING | NCT06413433 |
| Solriamfetol 150 mg | Other | Phase PHASE3 | Binge-Eating Disorder | RECRUITING | NCT06413433 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Other | Phase PHASE3 | Binge-Eating Disorder | ENROLLING_BY_INVITATION | NCT06878976 |
| Placebo | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 300 mg | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 150 mg | Other | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Placebo | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT05557409 |
| AXS-05 | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT05557409 |
| AXS-07 (meloxicam-rizatriptan) | Other | Phase PHASE3 | Migraine | COMPLETED | NCT05550207 |
| Placebo | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT04947553 |
| AXS-05 (dextromethorphan-bupropion) | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | COMPLETED | NCT04947553 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT06360419 |
| Solriamfetol 300 mg | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT06360419 |
| Placebo | Other | Phase PHASE4 | Excessive Daytime Sleepiness | COMPLETED | NCT04789174 |
| Solriamfetol | Other | Phase PHASE4 | Excessive Daytime Sleepiness | COMPLETED | NCT04789174 |
| AXS-05 (dextromethorphan-bupropion) | Other | Phase PHASE2 | Treatment Resistant Depression | TERMINATED | NCT04634669 |
| Placebo | Other | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| AXS-14 (Esreboxetine) | Other | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT05972044 |
| Solriamfetol 300 mg | Other | Phase PHASE3 | ADHD | COMPLETED | NCT05972044 |
| Solriamfetol 150 mg | Other | Phase PHASE3 | ADHD | COMPLETED | NCT05972044 |
| AXS-05 (dextromethorphan-bupropion) | Other | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | TERMINATED | NCT06736509 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| Solriamfetol 150 MG | Other | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| Dextromethorphan-Bupropion | Other | Phase PHASE2 | Major Depressive Disorder (MDD) | RECRUITING | NCT07523048 |
| Solriamfetol 150 MG | DRUG | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| AXS-14 (Esreboxetine) | DRUG | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| Solriamfetol 75mg, 150 mg, or 300 mg | DRUG | Phase PHASE3 | Binge-Eating Disorder | ENROLLING_BY_INVITATION | NCT06878976 |
| No treatment | OTHER | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Other prescription wake-promoting medications or stimulants | DRUG | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Sunosi (solriamfetol) | DRUG | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Solriamfetol 300 mg | DRUG | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 150 mg | DRUG | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Monitoring | OTHER | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | BEHAVIORAL | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Solriamfetol 75 MG | DRUG | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| AXS-07 (meloxicam-rizatriptan) | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT05550207 |
| AXS-12 (reboxetine) | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05113745 |
| Solriamfetol 150 mg Oral Tablet | DRUG | Phase PHASE1 | Narcolepsy | COMPLETED | NCT05008341 |
| Solriamfetol | DRUG | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Solriamfetol Oral Tablet | DRUG | Phase PHASE4 | Excessive Sleepiness | TERMINATED | NCT04788953 |
| AXS-05 (dextromethorphan-bupropion) | DRUG | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | TERMINATED | NCT06736509 |
| AXS-07 | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT04068051 |
| AXS-05 (dextromethorphan and bupropion) oral tablets | DRUG | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04039022 |
| Rizatriptan | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| Meloxicam | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| AXS-07 (MoSEIC meloxicam and rizatriptan) | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT04163185 |
| AXS-12 (Reboxetine) | DRUG | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| Bupropion SR | DRUG | Phase PHASE2 | Major Depressive Disorder | UNKNOWN | NCT04971291 |
| AXS-02 | DRUG | Phase PHASE3 | Osteoarthritis, Knee | UNKNOWN | NCT02746068 |
| Bupropion | DRUG | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| AXS-05 | DRUG | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| Placebo | DRUG | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| AXS-02 (oral zoledronate) | DRUG | Phase PHASE3 | Complex Regional Pain Syndrome | UNKNOWN | NCT02504008 |
Total products: 150